Metsera, Inc. Common Stock (MTSR) - Net Assets
Based on the latest financial reports, Metsera, Inc. Common Stock (MTSR) has net assets worth $449.23 Million USD as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($639.66 Million) and total liabilities ($190.43 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore MTSR operating cash flow to assess how effectively this company generates cash.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $449.23 Million |
| % of Total Assets | 70.23% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Metsera, Inc. Common Stock - Net Assets Trend (2022–2024)
This chart illustrates how Metsera, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Metsera, Inc. Common Stock for the complete picture of this company's asset base.
Annual Net Assets for Metsera, Inc. Common Stock (2022–2024)
The table below shows the annual net assets of Metsera, Inc. Common Stock from 2022 to 2024. For live valuation and market cap data, see MTSR market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $287.35 Million | +191.72% |
| 2023-12-31 | $98.50 Million | +12215.74% |
| 2022-12-31 | $-813.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Metsera, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 25633300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Comprehensive Income | $1.16 Million | 0.40% |
| Other Components | $543.34 Million | 189.09% |
| Total Equity | $287.35 Million | 100.00% |
Metsera, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Metsera, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nordstrom Inc
NYSE:JWN
|
$4.12 Billion |
|
SLM Corp
NASDAQ:SLM
|
$4.13 Billion |
|
Godrej Industries Limited
NSE:GODREJIND
|
$4.13 Billion |
|
Tanger Factory Outlet Centers Inc
NYSE:SKT
|
$4.13 Billion |
|
Adata Technology Co Ltd
TWO:3260
|
$4.12 Billion |
|
TransAlta Corp
TO:TA
|
$4.12 Billion |
|
Gland Pharma Limited
NSE:GLAND
|
$4.12 Billion |
|
Corporacion America Airports
NYSE:CAAP
|
$4.12 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Metsera, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 98,501,000 to 287,350,000, a change of 188,849,000 (191.7%).
- Net loss of 209,127,000 reduced equity.
- New share issuances of 398,000,000 increased equity.
- Other comprehensive income decreased equity by 1,592,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-209.13 Million | -72.78% |
| Share Issuances | $398.00 Million | +138.51% |
| Other Comprehensive Income | $-1.59 Million | -0.55% |
| Other Changes | $1.57 Million | +0.55% |
| Total Change | $- | 191.72% |
Book Value vs Market Value Analysis
This analysis compares Metsera, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 25.77x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | $-0.02 | $70.50 | x |
| 2023-12-31 | $1.97 | $70.50 | x |
| 2024-12-31 | $2.74 | $70.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Metsera, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -72.78%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.57x
- Recent ROE (-72.78%) is below the historical average (-40.23%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-731.70K |
| 2023 | -47.92% | 0.00% | 0.00x | 1.71x | $-57.06 Million |
| 2024 | -72.78% | 0.00% | 0.00x | 1.57x | $-237.86 Million |
Industry Comparison
This section compares Metsera, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,677,567
- Average return on equity (ROE) among peers: -58.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Metsera, Inc. Common Stock (MTSR) | $449.23 Million | 0.00% | 0.42x | $4.12 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $86.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.60 Billion |
| Abeona Therapeutics Inc (ABEO) | $42.37 Million | -200.47% | 0.88x | $323.66 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $183.46 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $804.47 Million |
| Arbutus Biopharma Corp (ABUS) | $203.00 Million | -189.21% | 0.36x | $854.72 Million |
| ABVC Biopharma Inc (ABVC) | $60.67K | -43.96% | 0.04x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $56.72 Million | -25.23% | 0.07x | $9.73 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $-52.67 Million | 0.00% | 0.00x | $3.63 Billion |
About Metsera, Inc. Common Stock
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to re… Read more